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NO was checked by nitrate reductase assay, the activity of inducible nitric oxide
synthase ( iNOS ) was determined using iNOS assay kit.
Results: In the early group, the relaxation response to ACh was increased signiﬁcantly
in HRT group than that in ovariectomized model group, while there was no difference
in the relaxation response to ACh between HRT group and ovariectomized model
group in the late group. And there were no difference in the relaxation response to
SNP between HRT group and ovariectomized model group in the early group and the
late group; In the early group, transmission electron microscopy images of aorta in
HRT group presented no swelling of endothelial cells, no vacuoles in tracytoplasmic,
successive internal elastic lamina, endothelial cells attachment to elastic plate closely
and regularly arranged smooth muscle cells compared to that in ovariectomized early
group. However, there was no difference in transmission electron microscopy images
between HRT group and ovariectomized model group in the late group; In the early
group, the serum level of NO increased markedly in HRT group compared to the
ovariectomized model group. In the late group, the serum level of NO in HRT group
was similar to ovariectomized model group; There were no obvious changes in aortic
iNOS content between HRT group and ovariectomized model group in the early group
as well as in the late group.
Conclusions: HRT improved endothelial destruction and endothelial-dependent
vasodilation in the early HRT model, which related to nitric oxide release from
endothelial cells. Aortic iNOS content didn’t increased with the extension of ovari-
ectomized time, and didn’t increased by HRT in the early group as well as in the late
group.
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Objectives: To explore the effects of resveratrol on the anti-infammatory and meta-
bolic modulation in the prevention of cardiovascular disease and stable coronary ar-
tery disease.
Methods: A systematic literature search was conducted to identify randomised
controlled trials of resveratrol in Pubmed. Reports of trials were sought that evaluated
the effects of reseratrol in patients with cardiovascular disesase risk factors and stable
coronary artery disease .Then according to the Cochrane Handbook for systematic
reviews, we estimate the qulity of the randomised controlled trials and collect the
useful information. At last, we choose the variable and process data with RevMan 5.0.
Results: 12 trials with data for 455 patients were identiﬁed by the literature search.
Resveratrol did not signiﬁcantly decrease the CRP (weighted mean difference (WMD)
-0.12mg/L, 95% CI -0.36 to 0.12, P>0.05), TNF-a (WMD -0.09pg/mL, 95% CI
-0.53-0.35, P>0.05), and IL-6 (WMD 0.01pg/mL, 95% CI -0.23-0.24, P>0.05) in
patients compared with placebo. But resveratrol could decrease IL-1b in the pool
analysis of 2 clinical trials with WMD -0.17pg/mL, 95% CI -0.27 -0.08, P<0.05. The
reveratrol supplementation brought some beneﬁts on glycemic control, which per-
formed the ability of reducing the HbA1c (WMD 0.08%, 95% CI 0.04-0.12, P<0.05),
however it was a pity that reveratrol could not improve the fasting glucose (WMD
0.03mmol/L, 95% CI from -0.04 to 0.10, P>0.05), even increased homeostasis model
of assesment of insulin resistance (WMD 0.88, 95% CI 0.77-0.98, P<0.05) and in
patients with high cardiovascular risk but without diabetes compared with placebo. At
the same time, the supplementation of resveratrol did not exert the signiﬁcant effect on
the secretion of leptin (WMD -0.49ng/mL, 95% CI -1.49-1.97, P>0.05) and adipo-
nectin (WMD 0.13ug/mL, 95% CI -0.23 to 0.48, P>0.05).
Conclusions: According to the existed evidences, resveratrol supplementation did not
bring beneﬁts on the metabolic modulation and anti- inﬂammatory effects. Then
because of the number of clinical trials and the samples of these reports were small, we
need more large and multicenter to clarify the effects of resveratrol on cardiovascluar
protection.
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Objectives: Hyperhomocysteinemia is a well known risk factor for cardiovascular
disease. However, although increased plasma homocysteine levels have been widely
documented in overt hypothyroidism patients, their changes in subclinical hypothy-
roidism (SCH) patients remains controversial: a few of studies have shown that tHcy
level is elevated in SCH, while the others are conﬂicting. The aim of this meta-
analysis is to review the current data available in an effort to determine the associationJACC Vol 64/16/Suppl C j October 16–19, 2014 j GW-ICC Abstracts/Obetween SCH and hyperhomocysteinemia, as well as associations between SCH and
various metabolic/cardiovascular risk factors.
Methods:We searched PUBMED, EMBASE and COCHRANE LIBRARY databases
prior to September 2013 to identify studies that reported plasma homocysteine levels
in patients with SCH compared with euthyroid subjects. Two reviewers independently
evaluated every potential study for eligibility, assessed the methodological quality,
and extracted the data. Most of the included articles are observational studies, so we
conducted and reported this analysis according to the guidelines of the Meta-analysis
of Observational Studies in Epidemiology Group. We extracted the mean level as well
as the standard deviation of tHcy in SCH and euthyroid subjects from each study. All
the statistical analysis in this study was performed by using STATA 12 (Stata, College
Station, Texas, 77845 USA). The weighted mean difference (WMD) and 95% CIs of
tHcy, folate and vitamin B12, as well as some metabolic parameters such as BMI,
FPG, TG, HDL, LDL-C, were calculated in each study.
Results: We ﬁnally included nine studies with 443 patients and 367 controls from 33
articles in this meta- analysis. The pooled result of the weighted mean difference
(WMD) of increased tHcy levels was 0.96 mmol/L (95% CI 0.14-1.78; P¼0.022). And
the analysis of metabolic parameters showed that SCH was associated with a signif-
icant increase of body mass index (WMD, 1.331.33 kg/m2, 95% CI 0.62-2.04;
P<0.01), systolic blood pressure (WMD, 10.89 mmHg, 95% CI 6.55, 15.23; P<0.01),
diastolic blood pressure (WMD, 7.20mmHg, 95% CI 5.02-9.37; P<0.01), triglyceride
levels (WMD, 0.32 mmol/l, 95% CI 0.19-0.64; P<0.01), total cholesterol levels
(WMD, 0.53 mmol/l, 95% CI 0.36, 0.71; P<0.01), and low-density lipoprotein levels
(WMD, 0.28 mmol/l, 95% CI 0.14-0.42; P<0.01). Though the analysis of folate
showed lack of statistical difference, there was a decrease tendency in SCH patients
(WMD, -0.55ng/ml, 95% CI -1.10-0.00; P¼0.051). Other parameters such as HDL
(WMD, -0.04mmol/l, 95% CI -0.09-0.02; P¼0.178), vitamin B12 (WMD, -1.90pg/ml,
95% CI -23.93-20.13; P¼0.723), there are no signiﬁcant differences between the two
groups. While for vitamin B6, we could not perform an analysis since the enrolled
studies did not provide sufﬁcient data to calculate the 95% CI of vitamin B6 levels. As
the data provide in each study is insufﬁcient, we could not analyze the associations
between the homocysteine levels and these parameters.
Conclusions: Our analysis of nine observational studies with 443 patients showed that
SCH is associated with an increased plasma homocysteine levels. As for other
traditional risk factors for CVD, SCH is associated with a signiﬁcant increase in BMI,
SBP, DBP, TG, TC and LDL-C. And given to the higher risk of coronary artery
disease, all these ﬁndings emphasize the necessity of earlier screening and treating of
SCH.
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Objectives: Cytochrome P450 (CYP) 2C19 gene polymorphism and coronary heart
disease in Yunnan Han population correlation.
Methods: Randomly selected from September 2012 to December 2013 at the First
Afﬁliated Hospital of Kunming Medical College of Cardiology hospital and unrelated
Yunnan Han population 127 cases for the study, microarray assay using blood sam-
ples selected in the CYP2C19 gene sequence DNA single nucleotide polymorphisms
(single nucleotide polymorphism, SNP) genotype CYP2C19*1, CYP2C19*2,
CYP2C19*3, analysis of genotype and allele frequencies, realize the feature of
CYP2C19 polymorphisms inYunnan Han population; To be divided the population
into three classes (extensive metabolisers, intermediate metabolizers, and poor
metabolizers) by the basis of metabolic phenotype deﬁnition and the result of geno-
type. Group of 63 patients with coronary artery disease and 64 patients in the control
group to analyze the genetic polymorphisms, analyze the correlation of gene poly-
morphism and coronary heart disease.
Results: Genetic analysis: CYP2C19 genotype is given priority to with wild type in
Yunnan Han population, CYP2C19*1, CYP2C19*2 and CYP2C19*3 3 alleles fre-
quency of occurrence was 66.9%, 28.4% and 4.7%;Of CYP2C19 metabolic pheno-
type deﬁnition intermediate metabolizers highest frequency (47.2%), followed by
extensive metabolisers (43.3%), poor metabolizers (9.5%) the lowest; CYP2C19*1/
*1, CYP2C19*1/*2, CYP2C19*1/*3, CYP2C19*2/*2, CYP2C19*2/*3 and
CYP2C19*3/*3 genotype frequency was 43.3%, 42.5%, 4.7%, 5.5%, 3.2% and 0.8%.
Two groups of CYP2C19 genotype distribution accords with Hardy Weinberg equi-
librium; CYP2C19*1, CYP2C19*2, CYP2C19*3 allele in CHD group were 56.3%,
37.3%, 6.4%, in the control group were 77.3%, 19.5%, 3.2%, Allele frequency dis-
tribution between the two groups was statistically difference (P<0.05); CYP2C19*1/
*1, CYP2C19*1/*2, CYP2C19*1/*3, CYP2C19*2/*2, CYP2C19*2/*3 and
CYP2C19*3/*3 genotype in the CHD group were 25.4%, 55.6%, 6.3%, 7.9%, 3.2%
and 1.6%, in the control group was 60.9%, 29.8%, 3.1%, 3.1%, 3.1% and 0, between
the two groups genotypes were statistically difference (P<0.05); Logistic regression
analysis: In addition to traditional risk factors after age, sex, hypertension, diabetes,
high cholesterol, etc., CYP2C19*1/*2 gene mutation signiﬁcantly increased risk of
coronary heart disease (OR¼5.24, 95% CI 2.00-13.72), CYP2C19*1/*3 gene muta-
tion was also signiﬁcantly increased the risk (OR¼4.54, 95% CI 0.55-37.08).
CYP2C19 polymorphism is an important risk factor for coronary heart disease in
Yunnan Han population.
Conclusions: CYP2C19 polymorphism may increase the risk of coronary heart
disease in Yunnan Han population.thers C243
